Table 2.

Within-Person Percentage Changes and Day of Largest Change in Hemoglobin (Hb) Concentrations, by Primaquine (PQ) Treatment Group

Treatment Group	Largest Change Between Days 0 and 10		Change From Days 0 to 7		Change From Days 0 to 28		Mean Follow-up Day of Largest Change, Mean (95% CI)
	Percentage (95% CI)a	P b	Percentage (95% CI)a	P b	Percentage (95% CI)a	P b
Part 1
G6PD-n control groupc (n = 7)	−7.89 (−11.4 to −4.37)		−2.13 (−8.10–3.84)		−2.49 (−6.88–1.91)		7.9 (5.0–10.8)
G6PD-d group, by PQ dose
0.40 mg/kg (n = 4)	−16.8 (−24.7 to −8.93)	<.001	−7.53 (−19.2–4.11)	.009	−1.00 (−19.4–17.4)	.215	7.0 (3.6–10.4)
0.45 mg/kg (n = 7)	−7.63 (−12.5 to −2.75)	.662	−4.62 (−10.9–1.68)	.587	−2.33 (−8.99–4.32)	.638	9.4 (1.6–17.2)
0.50 mg/kg (n = 7)	−9.72 (−13.5 to −5.90)	.320	−3.77 (−9.77–2.23)	.606	−0.754 (−6.67–5.16)	.481	7.7 (3.9–11.5)
Part 2
Age 11–17 y
G6PD-n group (n = 7)	−6.86 (−11.3 to −2.46)		0.314 (−3.69–4.31)		−0.662 (−5.23–3.90)		9.0 (.9–17.1)
G6PD-d group (n = 7)	−11.5 (−16.1 to −6.96)		−6.89 (−10.5 to −3.30)	.006	−6.59 (−13.5–.300)	.111	13.4 (4.0–22.8)
Age 5–10 y
G6PD-n group (n = 7)	−5.24 (−10.2 to −.252)		4.46 (−3.01–11.9)		1.89 (−6.62–10.4)		7.6 (−1.8–16.9)
G6PD-d group (n = 5)	−9.61 (−16.1 to −3.08)	.199	0.017 (−13.2–13.3)	.378	−1.02 (−11.9–9.89)	.407	11.4 (4.1–18.7)

Part 1 was a PQ dose de-escalation trial in men (age ≥18 years). Part 2 was an age de-escalation trial in boys given 0.40 mg/kg PQ.

Abbreviations: CI, confidence interval; G6PD-d, glucose-6-phosphate dehydrogenase deficient; G6PD-n, glucose-6-phosphate dehydrogenase normal; Hb, hemoglobin.

^aNegative values indicate drops in the Hb level.

^bAdjusted for baseline Hb level. Within age groups, we used a regression model that adjusted for baseline Hb level to compare G6PD-d and G6PD-n participants.

^cReceived 0.50 mg/kg PQ.